Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to irinotecan combination chemotherapy

References

• Ailawadhi S, Sunga A, Rajput A, Yang GY, Smith J, Fakih M. (2006). Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer. Oncology 70:49–53.
   PubMed Web of Science ®Google Scholar
• Aquino A, Formica V, Prete SP, Correale PP, Massara MC, Turriziani M, De Vecchis L, Bonmassar E. (2004). Drug-induced increase of carcinoembryonic antigen expression in cancer cells. Pharmacol Res 49:383–96.
   PubMed Web of Science ®Google Scholar
• Aquino A, Prete SP, Greiner JW, Giuliani A, Graziani G, Turriziani M, De Filippi R, Masci G, Bonmassar E, De Vecchis L. (1998). Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells. Clin Cancer Res 4:2473–81.
   PubMed Web of Science ®Google Scholar
• Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP. (1989). Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 57:327–34.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. (2004). Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–45.
   PubMed Web of Science ®Google Scholar
• Fletcher RH. (1986). Carcinoembryonic antigen. Ann Intern Med 104:66–73.
   PubMed Web of Science ®Google Scholar
• Hanke B, Riedel C, Lampert S, Happich K, Martus P, Parsch H, Himmler B, Hohenberger W, Hahn EG, Wein A. (2001). CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA). Ann Oncol 12:221–6.
   PubMed Web of Science ®Google Scholar
• Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. (2005). Cancer statistics, 2005. CA Cancer J Clin 55:10–30.
   PubMed Web of Science ®Google Scholar
• Li YH, An X, Xiang XJ, Wang ZQ, Wang FH, Feng F, Jiang WQ, He YJ, Xu RH. (2009). [Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy.]. Ai Zheng 28:939–44.
   PubMedGoogle Scholar
• Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr. (2006). ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24:5313–27.
   PubMed Web of Science ®Google Scholar
• Meyerhardt JA, Mayer RJ. (2005). Systemic therapy for colorectal cancer. N Engl J Med 352:476–87.
   PubMed Web of Science ®Google Scholar
• Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Tangen C. (1993). An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. Jama 270:943–7.
   PubMed Web of Science ®Google Scholar
• Ohtsukasa S, Okabe S, Yamashita H, Iwai T, Sugihara K. (2003). Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs. J Cancer Res Clin Oncol 129:719–26.
   PubMed Web of Science ®Google Scholar
• Prete SP, Turriziani M, Massara MC, De Rossi A, Correale P, De Vecchis L, Torino F, Bonmassar L, Aquino A. (2008). Combined effects of 5-fluorouracil, folinic acid and oxaliplatin on the expression of carcinoembryonic antigen in human colon cancer cells: pharmacological basis to develop an active antitumor immunochemotherapy. J Exp Clin Cancer Res 27:5.
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J. (2008). Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–9.
   PubMed Web of Science ®Google Scholar
• Sorbye H, Dahl O. (2004). Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Acta Oncol 43:495–8.
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–16.
   PubMed Web of Science ®Google Scholar
• Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, De Gramont A. (2004). FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–37.
   PubMed Web of Science ®Google Scholar
• Trillet-Lenoir V, Chapuis F, Touzet S, Barbier JY, Freyer G, Gaudin JL, Lombard-Bohas C, Valette PJ, Lledo G, Gouttebel MC, Boyer JD, Chassignol L, Hamon H, Claudel-Bonvoisin S, Leprince E, Amoyal P, Glehen O, Darnand P, Heilmann M, O Bleuse, JP. (2004). Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas? Clin Oncol (R Coll Radiol) 16:196–203.
   PubMed Web of Science ®Google Scholar
• Wang WS, Lin JK, Lin TC, Chiou TJ, Liu JH, Yen CC, Chen WS, Jiang JK, Yang SH, Wang HS, Chen PM. (2002). Tumor marker CEA in monitoring of response to tegafur-uracil and folinic acid in patients with metastatic colorectal cancer. Hepatogastroenterology 49: 388–92.
   PubMedGoogle Scholar